BRAIN Biotech AG's Earnings Update: Analysts Adjust Forecasts

BRAIN Biotech AG (ETR:BNN), a German industrial biotechnology company, recently reported its annual results, leading analysts to update their forecasts. The company's earnings for the full year 2024 were released on January 16, 2025, with a loss per share of €0.51. This was a decrease from the previous year's loss of €0.38. The earnings per share (EPS) of -€0.51 was lower than the consensus estimate of -€0.38, indicating that the company's earnings did not meet analyst expectations.

Following the earnings release, analysts have been updating their forecasts for BRAIN Biotech AG. Some key updates include:

* Consensus EPS estimates fall by 12% (Jun 06)
* Revenue growth (YoY) projection changes from 11.79% to 1.29% (Jan 17)
* Revenue projection for the fiscal year 2024 changes from €56.23 million to €55.52 million (Jan 17)
* Revenue projection for the fiscal year 2025 changes from €50.3 million to €55.52 million (Jan 17)
* Revenue projection for the fiscal year 2026 changes from €39.22 million to €55.52 million (Jan 17)
* Revenue projection for the fiscal year 2027 changes from €39.06 million to €55.52 million (Jan 17)
* Revenue projection for the fiscal year 2028 changes from €21.82 million to €55.52 million (Jan 17)
* Revenue projection for the fiscal year 2029 changes from €21.61 million to €55.52 million (Jan 17)
* Revenue projection for the fiscal year 2030 changes from €19.26 million to €55.52 million (Jan 17)

These updates reflect analysts' revised expectations for the company's performance following the earnings release. The changes in revenue growth projections and revenue forecasts for future fiscal years suggest that analysts are adjusting their views on the company's financial outlook.